← All Korro Bio, INC filings

Korro Bio, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
KRRO
Korro Bio, INC
10-K: Korro Bio Pivots AATD Strategy, Eyes 2026 Clinical Filings
Korro Bio reports significant losses and a strategic shift in its AATD program after a clinical setback, while advancing its hyperammonemia candidate and securing new funding.
NASDAQ
KRRO
Korro Bio, INC
10-K: Korro Bio Reports 2024 Results, Highlights Progress in RNA Editing Therapies
Korro Bio advances its RNA editing platform with clinical trial initiation and pipeline development, while reporting a net loss for 2024.
NASDAQ
KRRO
Korro Bio, INC
10-K: Korro Bio Outlines RNA Editing Platform and Pipeline in 10-K Filing
Korro Bio's 10-K filing details its RNA editing platform, OPERA, and its pipeline of therapeutic programs targeting various diseases.